Castle Biosciences Stock Price, News & Analysis

Castle Biosciences (Nasdaq: CSTL) reported new data showing its DecisionDx-Melanoma test improves sentinel lymph node biopsy (SLNB) decision-making and recurrence risk prediction in cutaneous melanoma. Two oral presentations will occur at ECDO on Nov 17–18, 2025.

The i31-SLNB algorithm outperformed the MIA nomogram (AUC=0.74 vs. 0.61; p=0.001), identifying a 2.6% actual SLN positivity rate for patients predicted <5% risk versus 5.8% by MIA. In a multicenter study of 810 SLN-negative patients, the 31-GEP independently predicted poorer five-year outcomes (Class 2B vs others; p<0.001) and improved prognostic accuracy when added to AJCC staging (ANOVA χ²=7.75, p=0.02).

Castle Biosciences (NASDAQ: CSTL) said its executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025 at 1:10 p.m. ET. A live audio webcast will be available at the company’s investor events page and a replay will be posted after the live broadcast.

Castle Biosciences (Nasdaq: CSTL) reported Q3 2025 revenue of $83.0 million and delivered 26,841 total test reports. The company raised full‑year 2025 revenue guidance to $327–335 million from $310–320 million and launched AdvanceAD‑Tx, a 487‑gene expression test for systemic treatment decisions in moderate‑to‑severe atopic dermatitis (ages 12+).

Core test volumes grew: DecisionDx‑Melanoma 10,459 and TissueCypher 10,609 reports in Q3; core revenue drivers test reports increased 36% year‑over‑year. The Novitas LCD excluding DecisionDx‑SCC (effective April 24, 2025) and discontinuation of IDgenetix affected revenue and volumes.

Castle Biosciences (Nasdaq: CSTL) launched AdvanceAD-Tx on November 3, 2025, a 487-gene expression profile test to guide systemic treatment choice for patients aged 12+ with moderate-to-severe atopic dermatitis.

Validation data showed 30.4% of samples had a JAK inhibitor responder profile; those treated with JAKi reached EASI-90 by three months at 45.5% vs 8.3% (p=0.021), had higher vIGA-AD clear rates (36.4% vs 0%, p=0.006), more “no itch” reports (45.5% vs 8.3%, p=0.021), and remained flare-free more often (54.5% vs 16.7%, p=0.041).

Castle estimates a U.S. TAM of $33 billion, is pursuing reimbursement pathways, and is beginning a measured limited-access commercial launch in November 2025 with phased expansion through 2026.

Castle Biosciences (Nasdaq: CSTL) said its executive management will present a company overview at the Stephens 27th Annual Investment Conference on Nov 19, 2025 at 10:00 a.m. ET. A live audio webcast will be available at the company’s investor website and a replay will be posted after the broadcast. Castle also will be available for one-on-one investor meetings at the Jefferies Global Healthcare Conference on Nov 18–20, 2025, with meetings requestable through Jefferies Financial Group.

Castle Biosciences (Nasdaq: CSTL) presented new data at ACG 2025 showing the TissueCypher test provides risk insights beyond pathology and influenced clinical management in multiple Barrett’s esophagus cohorts.

Key highlights: TissueCypher returned five-year progression probabilities of 34%, 62%, 43% and 45% in case studies, exceeded published HGD→EAC five-year rate of 33%, and influenced management in 93% of 114 rural NDBE patients; three posters were presented, one received a Presidential Poster Award.

Castle Biosciences (Nasdaq: CSTL) announced presentation of validation data showing its DecisionDx-Melanoma test stratified risk across histological subtypes in a real-world cohort of 13,560 stage I–III cutaneous melanoma patients.

Key findings include five-year melanoma-specific survival differences by test class (example: nodular melanoma 98.5% vs 82.3% for Class 1A vs 2B) and higher early distant-metastasis rates in Class 2B (AJCC stage I–II cohort n=1,661; CNS 7.4% vs 0.9%).

Castle also presented prospective, multicenter data (49 U.S. sites) for a 487-gene atopic dermatitis GEP that identifies a JAKi responder profile to guide systemic therapy selection.

Castle Biosciences (Nasdaq: CSTL) will release financial results for the third quarter and nine months ended Sept. 30, 2025 after market close on Monday, Nov. 3, 2025.

Management will host a conference call and webcast at 4:30 p.m. Eastern the same day. A live webcast is available at the company investor relations site or via https://events.q4inc.com/attendee/153584002. U.S. phone access is 1-833-470-1428 (access code 735311); international numbers are listed at the provided global numbers link. Attendees are asked to connect at least 10 minutes early. A replay will be available after the call and a brief Q&A will follow management remarks.

Castle Biosciences (Nasdaq: CSTL) announced that its founder, president and CEO Derek Maetzold has been named CEO of the Year by The CEO Magazine, selected from 586 applicants in their 2025 Executive of the Year Awards program.

Under Maetzold's leadership, Castle has evolved from a startup into a leading diagnostics company with nearly 800 employees. The company has developed proprietary tests for skin cancers, Barrett's esophagus, and uveal melanoma. Castle has also earned recognition as a Top Workplace USA for four consecutive years, reflecting its strong people-first culture and values-driven approach to corporate growth.